About Veradermics Inc
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.veradermics.com/
Frequently Asked Questions
What is the 52-week range for MANE?
The 52-week high is $131.2399 and the 52-week low is $32.
What is the P/E ratio for MANE?
The P/E ratio data is currently unavailable.
What is the dividend yield for MANE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -35.49%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for MANE over the last few months:
Latest MANE News
Veradermics: Buy Before The Catalysts
Veradermics (MANE) stock outlook: Phase 3 VDPHL01 readouts, FDA approval odds, cash runway, and hair loss market upsideâsee the bull case and act now.
HQL: The Rally That Makes Growth Harder (Rating Downgrade)
HQL downgraded to Hold after big rally; 12.5% yield, NAV discount and payout risks weigh on upside.
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]
Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Veradermics, Incorporated (MANE) Citigroupâs Biopharma Back to School Summit 2026 September 9, 2026 3:00 PM EDTCompany ParticipantsReid Waldman - CEO &...
Veradermics to Present at Upcoming September Investor Conferences
NEW HAVEN, Conn., September 03, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September:
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Veradermics has delivered a very strong year-to-date share price gain, yet the valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up 160.8% year to date, which means anyone buying now is stepping in after a very sharp re-rating. Future valuation for Veradermics can hinge on how effectively the company converts its growth opportunities into durable cash flow, while any stumble on execution or profitability could...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Hollander David | +19,300 | - | - |
| 2026-09-01 | Hollander David | +9,650 | - | - |
| 2026-08-20 | MONTANOVA CAPITAL, LLC | -151,000 | - | - |
| 2026-08-20 | MONTANOVA CAPITAL, LLC | -149,000 | - | - |
| 2026-08-20 | MONTANOVA CAPITAL, LLC | +151,000 | - | - |
| 2026-08-20 | MONTANOVA CAPITAL, LLC | +149,000 | - | - |
| 2026-08-19 | MONTANOVA CAPITAL, LLC | -59,399 | $107.25 | $6,370,543 |
| 2026-08-19 | MONTANOVA CAPITAL, LLC | -690,601 | $107.25 | $74,066,957 |
| 2026-08-17 | Durso Timothy August | -3,452 | - | - |
| 2026-08-17 | Durso Timothy August | -161 | $111.28 | $17,916 |
| 2026-08-17 | Durso Timothy August | -2,348 | $109.34 | $256,730 |
| 2026-08-17 | Durso Timothy August | -16,767 | $108.38 | $1,817,207 |
| 2026-08-17 | Durso Timothy August | -16,306 | $107.52 | $1,753,221 |
| 2026-08-17 | Durso Timothy August | -7,918 | $106.71 | $844,930 |
| 2026-08-17 | Durso Timothy August | +3,452 | $12.19 | $42,080 |
| 2026-08-17 | Waldman Reid Alexander | -3,452 | - | - |
| 2026-08-17 | Waldman Reid Alexander | -249 | $111.28 | $27,709 |
| 2026-08-17 | Waldman Reid Alexander | -3,000 | $109.38 | $328,140 |
| 2026-08-17 | Waldman Reid Alexander | -27,490 | $108.45 | $2,981,291 |
| 2026-08-17 | Waldman Reid Alexander | -25,234 | $107.53 | $2,713,412 |
| 2026-08-17 | Waldman Reid Alexander | -11,527 | $106.72 | $1,230,161 |
| 2026-08-17 | Waldman Reid Alexander | +3,452 | $12.19 | $42,080 |
| 2026-08-12 | CHILDS JOHN W | -5,000 | $108.24 | $541,200 |
| 2026-08-12 | CHILDS JOHN W | -80,000 | $107.23 | $8,578,400 |
| 2026-08-12 | CHILDS JOHN W | -15,000 | $106.14 | $1,592,100 |
| 2026-05-01 | SUVRETTA CAPITAL MANAGEMENT, LLC | +151,000 | $99.9999 | $15,099,985 |
| 2026-05-01 | SUVRETTA CAPITAL MANAGEMENT, LLC | +149,000 | $99.9999 | $14,899,985 |
| 2026-02-05 | CHILDS JOHN W | +294,117 | $17 | $4,999,989 |